Lasa Supergenerics Limited

BSE: 540702 NSE: LASA
Lasa Supergenerics Limited - pharma in Khed, Maharashtra, India. FY 2026 financials & compliance.
CIN L24233MH2016PLC274202 Incorporated 11 March 2016 ROC Mumbai HQ Khed, Maharashtra, India
Active Listed - NSE: LASA · BSE: 540702 Public Limited Company pharma
Data last updated
Market Cap
₹29.51 Cr
LASA · NSE
Share Price
₹5.60
-4.92% today
Revenue
₹25.14 Cr
FY 2025-26 · -64.7% YoY
EBITDA
−₹28.40 Cr
Margin -113.0%
Net Profit
−₹13.05 Cr
FY 2025-26
P/E (TTM)
0.0x
P/B 0.6x

About Lasa Supergenerics Limited

Data last updated: 28 September 2026

Lasa Supergenerics Limited is a public limited company based in Khed, Maharashtra, India, a subsidiary of Omkar Speciality Chemicals Limited. It specialises in animal pharmaceuticals and healthcare, a part of the broader pharmaceuticals sector. Incorporated on 11 March 2016, the company has been in operation for over 10 years.

Registered with ROC Mumbai under CIN L24233MH2016PLC274202. Listed on BSE: 540702 and NSE: LASA.

Capital: an authorised share capital of ₹100.33 Cr and a paid-up capital of ₹5.01 Cr. It is led by directors including Omkar Pravin Herlekar and Ketan Bhau Songal.

Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Khed, Maharashtra.

As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹25.14 Cr, a decline of 82.35% compared to the previous year.

The company has a workforce of approximately 326 employees as per the latest available data. It operates as a subsidiary of Omkar Speciality Chemicals Limited.

As per MCA filings, the company has satisfied charges of ₹84.64 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website lasalabs.com.

Company Details of Lasa Supergenerics Limited
CIN L24233MH2016PLC274202
Registration Number 274202
Incorporation Date 11 March 2016
ROC Mumbai
Listing Status Listed (BSE: 540702, NSE: LASA)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Parent Company Omkar Speciality Chemicals Limited
Compliance Status Active Compliant
Key People
Omkar Pravin Herlekar Managing Director Ketan Bhau Songal Director Pravin Gadalya Lachake Director
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    lasalabs.com
  • Social Media
  • Registered Address
    Plot No. C – 4 C – 4/1 Midc Lote Parshuram Industrial Area Tal – Khe, D, Khed, Maharashtra, India – 415722
  • Industry
    Pharma, Animal Pharmaceuticals & Healthcare
Company report
Lasa Supergenerics Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Lasa Supergenerics Limited report

Financials, compliance, directors, charges, ownership and filings for Lasa Supergenerics Limited in one report.

10-year financials Directors & ownership Charges & compliance

CIN History of Lasa Supergenerics Limited

Lasa Supergenerics Limited has one previous CIN (Corporate Identification Number): U24233MH2016PLC274202. The current CIN is L24233MH2016PLC274202, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24233MH2016PLC274202 Current
U24233MH2016PLC274202 Previous

Business Activity of Lasa Supergenerics Limited

Lasa Supergenerics Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products Locked
Premium access

Business activity turnover details for Lasa Supergenerics Limited

Turnover contribution percentages and historical activity changes require an active report plan.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Verified entity values are shown only after access is granted.

Auditor Details of Lasa Supergenerics Limited

Lasa Supergenerics Limited is audited by THANAWALA & Co for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
THANAWALA & Co Locked Locked Locked
Premium access

Complete auditor history for Lasa Supergenerics Limited

Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.

  • Appointment status
  • Appointment dates
  • Cessation dates
  • Auditor changes

Verified entity values are shown only after access is granted.

Board of Directors of Lasa Supergenerics Limited

Lasa Supergenerics Limited is currently managed by 6 directors, with 15 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Omkar Pravin Herlekar
Also directs: Lasa Supergenerics Limited, Lasa Lifesciences Private Limited, Dr. Omkar Herlekar Foundation
Managing Director 11 Mar 2016 10 Years 6 Months Current
Ketan Bhau Songal
Also directs: Lasa Supergenerics Limited
Director 04 Aug 2025 1 Years 1 Months Current
Pravin Gadalya Lachake
Also directs: Lasa Supergenerics Limited
Director 04 Aug 2025 1 Years 1 Months Current
Yogesh Hari Ughada
Also directs: Lasa Supergenerics Limited
Director 04 Aug 2025 1 Years 1 Months Current
Rekha Hemant Wakh
Also directs: Lasa Supergenerics Limited
Director 04 Aug 2025 1 Years 1 Months Current
Ganesh Suresh Potdar
Also directs: Lasa Supergenerics Limited
Additional Director 02 Jan 2026 0 Years 8 Months Current
View all directors

Financials of Lasa Supergenerics Limited FY 2025-26 filings available

Lasa Supergenerics Limited reported revenue of ₹25.14 Cr (down 82.35% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹25.14 Cr
-82.4% YoY
EBITDA
−₹28.40 Cr
-201.8% YoY
Profit After Tax
−₹13.05 Cr
-1534.1% YoY
Net Worth
-
Total Assets
-
Total Debt
-

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue25.14142104130137202167
Revenue growth-64.7%+37.0%-28.9%+21.0%-16.8%+12.9%-13.4%
EBITDA(28.40)(9.41)(6.55)(26.46)8.1747.3229.95
EBITDA margin-113.0%-6.6%-6.3%-20.4%+6.0%+23.4%+17.9%
Profit before tax(34.61)(19.39)(19.11)(42.27)(6.13)29.504.72
Net profit(13.05)0.91(14.16)(19.40)2.4722.793.78
Net profit margin-51.9%+0.6%-13.6%-15.0%+1.8%+11.3%+2.3%
EPS (₹)(6.80)(2.95)(4.34)(7.71)(1.06)5.600.89
Balance sheet
Total assets-86.28119141179179190
Net worth-83.7196.68118158159141
Total debt-2.1322.0821.7720.1719.4648.41
Cash & bank-0.791.502.3917.224.406.06
Net working capital-17.4811.0918.2641.7243.2534.22
Cash flow
Cash from operations-(2.82)2.14(17.30)9.2141.3113.62
Cash from investing-8.15(0.40)11.19(2.91)(3.60)(1.63)
Cash from financing-(5.66)(1.93)(4.16)(0.04)(36.44)(9.85)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1.23(0.13)2.203.0620.0139.1433.0839.39
Revenue growth (YoY)-93.9%--93.4%-92.2%-35.1%+71.5%+24.1%+62.1%
Other income0.100.040.020.010.132.398.911.95
Total expenses3.102.452.957.0641.0959.6432.8238.60
EBITDA(1.87)(2.58)(0.75)(4.00)(21.08)(20.50)0.260.79
EBITDA margin-152.0%+1984.6%-34.1%-130.7%-105.3%-52.4%+0.8%+2.0%
Depreciation1.571.311.571.571.573.902.802.81
Interest0.140.130.110.120.030.110.471.24
Profit before tax(3.48)(3.98)(2.41)(5.68)(22.55)(22.12)5.90(1.31)
Tax0.110.190.140.57(1.42)(7.83)0.421.92

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 28 Sep 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1.23(0.13)2.203.0620.0139.1433.0839.39
Revenue growth (YoY)-93.9%--93.4%-92.2%-35.1%+71.5%+24.1%+62.1%
Other income0.100.040.020.010.132.398.911.95
Total expenses3.102.452.957.0641.0959.6432.8238.60
EBITDA(1.87)(2.58)(0.75)(4.00)(21.08)(20.50)0.260.79
EBITDA margin-152.0%+1984.6%-34.1%-130.7%-105.3%-52.4%+0.8%+2.0%
Depreciation1.571.311.571.571.573.902.802.81
Interest0.140.130.110.120.030.110.471.24
Profit before tax(3.48)(3.98)(2.41)(5.68)(22.55)(22.12)5.90(1.31)
Tax0.110.190.140.57(1.42)(7.83)0.421.92
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue25.14142104130137202167
Revenue growth-64.7%+37.0%-28.9%+21.0%-16.8%+12.9%-13.4%
Other income0.205.010.101.800.270.060.23
Total expenses53.54152111156129155137
Employee cost0.006.115.376.357.1514.0113.42
EBITDA(28.40)(9.41)(6.55)(26.46)8.1747.3229.95
EBITDA margin-113.0%-6.6%-6.3%-20.4%+6.0%+23.4%+17.9%
Depreciation6.0212.3010.6713.4214.5115.8217.34
Interest0.392.691.994.190.062.068.12
Profit before tax(34.61)(19.39)(19.11)(42.27)(6.13)29.504.72
Tax(0.52)(4.63)2.62(3.65)(0.81)6.721.11
Net profit(13.05)0.91(14.16)(19.40)2.4722.793.78
Net profit margin-51.9%+0.6%-13.6%-15.0%+1.8%+11.3%+2.3%
EPS (₹)(6.80)(2.95)(4.34)(7.71)(1.06)5.600.89
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-50.1050.1050.1050.1040.6740.67
Reserves & surplus-31.8646.5868.18108118101
Shareholders' funds (net worth)-83.7196.68118158159141
Secured loans-0.0022.0821.770.000.0034.04
Unsecured loans-2.130.000.0020.1719.4614.37
Total debt-2.1322.0821.7720.1719.4648.41
Total liabilities-86.28119141179179190
Assets
Gross block-128230229234226220
Net block-67.98110119137143152
Capital work in progress-0.252.514.644.580.000.00
Investments-0.000.000.390.380.000.00
Inventories-24.5019.0413.9011.5017.2626.30
Sundry debtors-1.493.592.4818.5614.7720.65
Cash & bank balances-0.791.502.3917.224.406.06
Loans & advances-5.7313.7620.4519.0227.9022.86
Total current assets-32.5137.8939.2266.3064.3375.87
Total current liabilities-15.0326.8020.9624.5821.0841.65
Net working capital-17.4811.0918.2641.7243.2534.22
Total assets-86.28119141179179190
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-0.610.8011.074.812.570.42
Net cash from operating activities-(2.82)2.14(17.30)9.2141.3113.62
Net cash from investing activities-8.15(0.40)11.19(2.91)(3.60)(1.63)
Net cash from financing activities-(5.66)(1.93)(4.16)(0.04)(36.44)(9.85)
Net change in cash-(0.33)(0.19)(10.27)6.261.272.15
Closing cash-0.791.502.3917.224.406.06
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-82.4%+36.5%-19.5%-5.5%-32.2%+21.0%-1.4%
EBITDA growth-201.8%-43.7%+75.3%--82.7%+58.0%+169.6%
PBT growth-78.5%-1.5%+54.8%-589.6%-+525.0%+9998.0%
Net income growth-+9998.0%+27.0%--89.2%+502.9%+9998.0%
Revenue CAGR (3Y)-42.1%+1.3%-19.8%-8.2%-6.8%-6.0%-5.6%
EBITDA CAGR (3Y)+2.4%----9.7%+4.6%+15.7%
Profitability & leverage
Net income margin-135.6%-10.4%-20.8%-29.8%-3.9%+11.3%+2.2%
Return on capital employed-0.0%0.0%0.0%+1.0%+17.1%+6.8%
Return on net worth-0.0%0.0%0.0%+1.6%+15.2%+2.9%
Debt / equity-0.130.200.150.130.230.54
Long-term debt / equity-0.000.000.000.000.050.24
Interest cover-1.13-12.39-11.56-10.51-0.956.5464.39
Efficiency & per share
Fixed asset turnover-0.800.450.560.600.910.78
Inventory turnover-6.546.3410.209.549.295.78
Debtors turnover-56.0834.3812.328.2311.436.75
EPS (₹)(6.80)(2.95)(4.34)(7.71)(1.06)5.600.89
Dividend per share (₹)0.000.000.000.000.250.250.00
Book value per share (₹)0.0016.3619.3023.6131.5139.0734.78
Want more history and ratios?
You're viewing the latest exchange-filed financials for Lasa Supergenerics Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Lasa Supergenerics Limited

As per the shareholding pattern for the quarter ended Jun 2026, promoters hold 53.60%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00%, retail and other public shareholders hold 46.40% of Lasa Supergenerics Limited.

Promoters: 53.60%Retail & Others: 46.40%
Jun 2026
QUARTER
53.60% Promoters
46.40% Retail & Others
Promoter holding - history
Now 53.60% · Jun 2026High 53.60% · Sep 2025Low 53.60% · Sep 2025
52%52.8%53.5%54.3%55%Sep 2025Dec 2025Mar 2026Jun 2026Sep 2025: 53.60%Dec 2025: 53.60%Mar 2026: 53.60%Jun 2026: 53.60%53.60%53.60%
Shareholding trend - last 6 quarters
Jun 2026Mar 2026Dec 2025Sep 2025
Promoters53.60%53.60%53.60%53.60%
Public46.40%46.40%46.40%46.40%

Charges & Borrowings of Lasa Supergenerics Limited

Open charges
₹0
Satisfied charges
₹84.64 Cr
Breakdown by lending institutions
Axis Bank Limited₹76.79 Cr
Others₹7.85 Cr
Latest charge details
DateLenderAmountStatus
26 Apr 2018 Others ₹6.03 Cr Satisfied
31 Mar 2018 Others ₹1.82 Cr Satisfied
28 Nov 2012 Axis Bank Limited ₹76.79 Cr Satisfied

Total charge records: 3 View all charges

Employees and EPFO Compliance at Lasa Supergenerics Limited

Lasa Supergenerics Limited has a workforce of 326 employees as of Apr 07, 2024.

Employee count
326
Active EPFO establishments
1
Employee growth
-3.55%
Premium access

Employee and EPFO history for Lasa Supergenerics Limited

Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.

  • Monthly headcount
  • PF contributions
  • ECR filing status
  • Establishment history

Verified entity values are shown only after access is granted.

GST Compliance of Lasa Supergenerics Limited

Premium access

GST registrations and filing compliance for Lasa Supergenerics Limited

State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.

  • GSTIN registrations
  • State-wise filing status
  • HSN and SAC details
  • Tax jurisdiction records

Verified entity values are shown only after access is granted.

Credit Ratings, Litigation & Regulatory Alerts for Lasa Supergenerics Limited

Premium access

Credit ratings, litigation, and regulatory alerts for Lasa Supergenerics Limited

Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.

  • Rating history
  • Court and tribunal cases
  • Regulatory alerts
  • Director-linked violations

Verified entity values are shown only after access is granted.

MSME Payment Delays by Lasa Supergenerics Limited

Premium access

MSME payment history for Lasa Supergenerics Limited

Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.

  • Outstanding amounts
  • Delay periods and reasons
  • MSME-1 filing history
  • Vendor payment signals

Verified entity values are shown only after access is granted.

Subsidiaries & Group Companies of Lasa Supergenerics Limited

Premium access

Corporate group structure for Lasa Supergenerics Limited

Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.

  • Parent company
  • Subsidiaries and ownership
  • Associates and joint ventures
  • Entity investments

Verified entity values are shown only after access is granted.

MCA Filings & Documents of Lasa Supergenerics Limited

Premium access

MCA filings and documents for Lasa Supergenerics Limited

Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.

  • Incorporation documents
  • Annual returns and statements
  • Charge filings
  • Complete filing index

Verified entity values are shown only after access is granted.

Recent Activity on Lasa Supergenerics Limited

Directors
09 Jan 2026
Mitti Mitesh Jain was appointed as a Company Secretary on 09 Jan 2026 & has been associated with this company since 8 months 19 days.
Directors
02 Jan 2026
Ganesh Suresh Potdar was appointed as a Additional Director on 02 Jan 2026 & has been associated with this company since 8 months 26 days.
Activity
30 Sep 2025
Lasa Supergenerics Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Directors
04 Aug 2025
Ketan Bhau Songal was appointed as a Director on 04 Aug 2025 & has been associated with this company since 1 year 1 month.
Directors
04 Aug 2025
Pravin Gadalya Lachake was appointed as a Director on 04 Aug 2025 & has been associated with this company since 1 year 1 month.
Directors
04 Aug 2025
Yogesh Hari Ughada was appointed as a Director on 04 Aug 2025 & has been associated with this company since 1 year 1 month.

Recent News on Lasa Supergenerics Limited

Frequently Asked Questions about Lasa Supergenerics Limited

Lasa Supergenerics Limited is an active public limited company in the pharma sector based in Khed, Maharashtra, India. It was incorporated on 11 March 2016 (10+ years old) and is registered under CIN L24233MH2016PLC274202. Listed on BSE: 540702 and NSE: LASA. The company has 326 employees.

Lasa Supergenerics Limited reported revenue of ₹25.14 Cr for FY 2025-26 (down 82.35% YoY) based on standalone financials.

The current directors of Lasa Supergenerics Limited are:

The primary industry of Lasa Supergenerics Limited is pharma. The company specifically operates in animal pharmaceuticals and healthcare. The company is currently active in this sector.

Yes. Lasa Supergenerics Limited is listed on both BSE (code: 540702) and NSE (symbol: LASA).

Lasa Supergenerics Limited can be reached at the registered office: Plot No. C – 4 C – 41 Midc Lote Parshuram Industrial Area Tal – Khe, D, Khed, Maharashtra, India – 415722, or through the website lasalabs.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available